Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Forex

Samsung Biologics Launches $1.9 Billion Bid for PolyPeptide

Guavy AI Editorial Team
Instruments
CHF
Share

Samsung Biologics is set to launch an all-cash takeover bid for PolyPeptide in September, offering 44.31 Swiss francs per share. The offer values the company at about $1.9 billion and represents a premium of around 40 percent over PolyPeptide's April 10 closing price.

The acquisition is part of Samsung Biologics' push into peptide manufacturing, specifically targeting the GLP-1 supply chain. This segment is experiencing rapid growth due to its applications in obesity and diabetes treatments.

PolyPeptide's board recommendation will weigh heavily on institutional shareholders' decisions during the offer period, which runs until October 12.

More on Forex

Forex just now

RBC Sees 117% Upside in Attovia Therapeutics Stock

Forex just now

Europe's Central Bankers Fear Turbulence from Unpredictable US Policy

Forex just now

Analysts Weigh in on Prudential Financial and Equitable Group

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy